Morgan Stanley Says Moderna's INT Outlook Strengthens on Melanoma Data
Morgan Stanley said Moderna's phase 3 adjuvant melanoma data strengthen its outlook for INT.
Morgan Stanley said Moderna's phase 3 adjuvant melanoma data strengthen its outlook for INT.